JP2023101521A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2023101521A5 JP2023101521A5 JP2023075706A JP2023075706A JP2023101521A5 JP 2023101521 A5 JP2023101521 A5 JP 2023101521A5 JP 2023075706 A JP2023075706 A JP 2023075706A JP 2023075706 A JP2023075706 A JP 2023075706A JP 2023101521 A5 JP2023101521 A5 JP 2023101521A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- halogen
- alkoxy
- ring
- ring structure
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16198731.8A EP3321264A1 (en) | 2016-11-14 | 2016-11-14 | Selective inhibitors of genotoxic stress-induced ikk/nf-kb pathways |
| EP16198731.8 | 2016-11-14 | ||
| JP2019524895A JP7307677B2 (ja) | 2016-11-14 | 2017-11-14 | 遺伝毒性ストレスにより誘導されるＩＫＫ／ＮＦ－κＢ経路の選択的阻害剤 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019524895A Division JP7307677B2 (ja) | 2016-11-14 | 2017-11-14 | 遺伝毒性ストレスにより誘導されるＩＫＫ／ＮＦ－κＢ経路の選択的阻害剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023101521A JP2023101521A (ja) | 2023-07-21 |
| JP2023101521A5 true JP2023101521A5 (enExample) | 2023-09-06 |
| JP7701403B2 JP7701403B2 (ja) | 2025-07-01 |
Family
ID=57288311
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019524895A Active JP7307677B2 (ja) | 2016-11-14 | 2017-11-14 | 遺伝毒性ストレスにより誘導されるＩＫＫ／ＮＦ－κＢ経路の選択的阻害剤 |
| JP2023075706A Active JP7701403B2 (ja) | 2016-11-14 | 2023-05-01 | 遺伝毒性ストレスにより誘導されるＩＫＫ／ＮＦ－κＢ経路の選択的阻害剤 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019524895A Active JP7307677B2 (ja) | 2016-11-14 | 2017-11-14 | 遺伝毒性ストレスにより誘導されるＩＫＫ／ＮＦ－κＢ経路の選択的阻害剤 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US11028084B2 (enExample) |
| EP (2) | EP3321264A1 (enExample) |
| JP (2) | JP7307677B2 (enExample) |
| CN (1) | CN109963850A (enExample) |
| AU (1) | AU2017359276B2 (enExample) |
| CA (1) | CA3041832A1 (enExample) |
| WO (1) | WO2018087389A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3321264A1 (en) * | 2016-11-14 | 2018-05-16 | Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft | Selective inhibitors of genotoxic stress-induced ikk/nf-kb pathways |
| CN113913515A (zh) * | 2020-07-10 | 2022-01-11 | 上海吉凯基因医学科技股份有限公司 | 人eme1基因的用途及相关产品 |
| CN111781358A (zh) * | 2020-07-13 | 2020-10-16 | 张瑜 | Xab2蛋白作为卵巢癌预后和/或预测铂类耐药标志物 |
| IL303620A (en) * | 2020-12-14 | 2023-08-01 | Kinoxis Therapeutics Pty Ltd | Oxytocin receptor modulators |
| CN120769853A (zh) * | 2022-12-13 | 2025-10-10 | 弗拉雷治疗公司 | 用于靶向tp53-y220c突变体的化合物和组合物 |
| EP4467141A1 (en) | 2023-05-24 | 2024-11-27 | Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft | Pyrazolo-quinolines as selective inhibitors of genotoxic stress-induced ikk/nf- kb pathways for cancer therapy |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3663559A (en) * | 1969-12-03 | 1972-05-16 | Union Carbide Corp | Preparation of oxo-furo-pyridines from furylvinyl isocyanates |
| CN100503607C (zh) * | 2003-06-02 | 2009-06-24 | 新疆华世丹药物研究有限责任公司 | 去氢骆驼蓬碱衍生物类化合物及其应用 |
| EP1989203A2 (en) * | 2006-02-16 | 2008-11-12 | Millennium Pharmaceuticals, Inc. | Alpha carbolines and uses thereof |
| TW200800978A (en) * | 2006-03-23 | 2008-01-01 | Otsuka Pharma Co Ltd | Carbazole compound |
| EP2227233B1 (en) * | 2007-11-30 | 2013-02-13 | Newlink Genetics | Ido inhibitors |
| JP5690715B2 (ja) * | 2008-03-28 | 2015-03-25 | アルテイリス・セラピユーテイクス | ケモカイン受容体調節因子 |
| CA2768466C (en) * | 2009-07-22 | 2018-08-14 | The Board Of Trustees Of The University Of Illinois | Hdac inhibitors and therapeutic methods using the same |
| EP2519238B1 (de) * | 2009-12-28 | 2014-08-13 | Audiocure Pharma GmbH | Beta-carboline zur behandlung von hörschäden und schwindel |
| CN102146080B (zh) * | 2010-02-10 | 2013-01-30 | 新疆华世丹药业股份有限公司 | β-咔啉碱衍生物类化合物及其应用 |
| US20120039804A1 (en) * | 2010-06-04 | 2012-02-16 | Philippe Diaz | Novel Tricyclic Modulators of Cannabinoid Receptors |
| CN111012779A (zh) * | 2011-10-25 | 2020-04-17 | 新疆华世丹药物研究有限责任公司 | 去氢骆驼蓬碱衍生物在制备抗菌药物中的应用 |
| PE20141996A1 (es) * | 2011-11-02 | 2014-11-28 | Bayer Ip Gmbh | Compuestos con actividad nematicida |
| US20150210717A1 (en) * | 2012-09-13 | 2015-07-30 | Baden-Württemberg Stiftung Gmbh | Specific inhibitors of protein p21 as therapeutic agents |
| EP3321264A1 (en) * | 2016-11-14 | 2018-05-16 | Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft | Selective inhibitors of genotoxic stress-induced ikk/nf-kb pathways |
-
2016
- 2016-11-14 EP EP16198731.8A patent/EP3321264A1/en not_active Withdrawn
-
2017
- 2017-11-14 EP EP17808365.5A patent/EP3538529B1/en active Active
- 2017-11-14 JP JP2019524895A patent/JP7307677B2/ja active Active
- 2017-11-14 CN CN201780071520.3A patent/CN109963850A/zh active Pending
- 2017-11-14 AU AU2017359276A patent/AU2017359276B2/en active Active
- 2017-11-14 WO PCT/EP2017/079181 patent/WO2018087389A1/en not_active Ceased
- 2017-11-14 CA CA3041832A patent/CA3041832A1/en active Pending
- 2017-11-14 US US16/349,580 patent/US11028084B2/en active Active
-
2023
- 2023-05-01 JP JP2023075706A patent/JP7701403B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023101521A5 (enExample) | ||
| JP2019529444A5 (enExample) | ||
| CN115244058A (zh) | 嘧啶并二环类衍生物、其制备方法及其在医药上的应用 | |
| CN113784970A (zh) | Erk抑制剂及其应用 | |
| RU2019100164A (ru) | Гетероциклическое соединение, используемое как ингибитор fgfr | |
| RU2011133128A (ru) | Противоопухолевые соединения дигидропиран-2-она | |
| CA2519898A1 (en) | Oral administration of cyclic protein tyrosine kinase inhibitors | |
| JP2019522055A5 (enExample) | ||
| RU2018138828A (ru) | Уменьшение массы опухоли путем введения ccr1 антагонистов в комбинации с pd-1 ингибиторами или pd-l1 ингибиторами | |
| RU2010106878A (ru) | Комбинация антимитотического агента и ингибитора аврора киназы как средство для лечения рака | |
| CN109328187A (zh) | 一种具有fgfr抑制活性的新型化合物及其制备和应用 | |
| JP2015517574A5 (enExample) | ||
| CN115605479A (zh) | 吡啶酮并嘧啶类衍生物、其制备方法及其在医药上的应用 | |
| JP2016503797A5 (enExample) | ||
| JP2010504346A5 (enExample) | ||
| RU2020102453A (ru) | Фармацевтические композиции | |
| CN110248662A (zh) | 一种治疗前列腺癌的组合、药物组合物及治疗方法 | |
| JP2019535709A5 (enExample) | ||
| JP2009539943A5 (enExample) | ||
| JP2007500734A5 (enExample) | ||
| JP2013542267A5 (enExample) | ||
| JP2017510660A5 (enExample) | ||
| RU2020119562A (ru) | Хиназолиноновое соединение и его применение | |
| JP2018507230A5 (enExample) | ||
| JP2020534266A5 (enExample) |